Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 Nov 3;113(9):1249-53.
doi: 10.1038/bjc.2015.269. Epub 2015 Oct 27.

Upcoming translational challenges for uveal melanoma

Nabil Amirouchene-Angelozzi  1 , Marie Schoumacher  2 , Marc-Henri Stern  3 , Nathalie Cassoux  4 , Laurence Desjardins  4 , Sophie Piperno-Neumann  5 , Olivier Lantz  6 , Sergio Roman-Roman  2
Affiliations
Review

Upcoming translational challenges for uveal melanoma

Nabil Amirouchene-Angelozzi et al. Br J Cancer. .

Erratum in

  • Upcoming translational challenges for uveal melanoma.
    Amirouchene-Angelozzi N, Schoumacher M, Stern MH, Cassoux N, Desjardins L, Piperno-Neumann S, Lantz O, Roman-Roman S. Amirouchene-Angelozzi N, et al. Br J Cancer. 2015 Dec 22;113(12):1746. doi: 10.1038/bjc.2015.456. Br J Cancer. 2015. PMID: 26695554 Free PMC article. No abstract available.

Abstract

The past few years have witnessed major advances in the understanding of the molecular landscape of uveal melanoma (UM). The discovery of a mutational background that is completely different from the one of skin melanoma has granted to UM a stand-alone status. The absence of effective therapy for metastatic disease offers now a chessboard for targeted therapy but at the same time urges preclinical science to develop accordingly, to guide the use of economical resources to the best profit of patients. This review describes the current knowledge on the biology of this disease and discusses the challenges that must be undertaken to translate this knowledge into real benefit for patients.

PubMed Disclaimer

References

    1. Aalto Y, Eriksson L, Seregard S, Larsson O, Knuutila S (2001) Concomitant loss of chromosome 3 and whole arm losses and gains of chromosome 1, 6, or 8 in metastasizing primary uveal melanoma. Invest Ophthalmol Vis Sci 42: 313–317. - PubMed
    1. Amirouchene-Angelozzi N, Nemati F, Gentien D, Nicolas A, Dumont A, Carita G, Camonis J, Desjardins L, Cassoux N, Piperno-Neumann S, Mariani P, Sastre X, Decaudin D, Roman-Roman S (2014) Establishment of novel cell lines recapitulating the genetic landscape of uveal melanoma and preclinical validation of mTOR as a therapeutic target. Mol Oncol 8: 1508–1520. - PMC - PubMed
    1. Augsburger JJ, Corrêa ZM, Shaikh AH (2009) Effectiveness of treatments for metastatic uveal melanoma. Am J Ophthalmol 148: 119–127. - PubMed
    1. Bidard F-C, Madic J, Mariani P, Piperno-Neumann S, Rampanou A, Servois V, Cassoux N, Desjardins L, Milder M, Vaucher I, Pierga J-Y, Lebofsky R, Stern M-H, Lantz O (2014) Detection rate and prognostic value of circulating tumor cells and circulating tumor DNA in metastatic uveal melanoma. Int J Cancer 134: 1207–1213. - PubMed
    1. Bol KF, Mensink HW, Aarntzen EHJG, Schreibelt G, Keunen JEE, Coulie PG, de Klein A, Punt CJA, Paridaens D, Figdor CG, de Vries IJM (2014) Long overall survival after dendritic cell vaccination in metastatic uveal melanoma patients. Am J Ophthalmol 158: 939–947. - PubMed